Global Pharmaceutical Markets

Published - May 2008| Analyst - Valarie Natale| Code - PHM037B
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

  • The global market for pharmaceuticals increased from $693.7 billion in 2007 to an estimated $737.6 billion by the end of 2008. It should reach over $1 trillion by 2013, a compound annual growth rate (CAGR) of 6.9%.
  • The generic prescription drugs segment will experience the highest growth rate over the study period. Worth an estimated $88.7 billion in 2008, it will reach $151.4 billion by the end of 2013, a CAGR of 11.3%.
  • The world’s best selling pharmaceutical product, Lipitor, had revenues of $12.7 billion in 2007.


This study examines world pharmaceutical markets and provides pertinent information about sales and production of pharmaceutical products, as well as information about national healthcare systems and drug pricing policies. The report covers 24 countries in detail and provides links to relevant information. There are also profiles of larger pharmaceutical and biotechnology companies, complete with revenue histories.
Trends in government policies concerning drug pricing and reimbursement are examined. The report also makes predictions about countries whose pharmaceutical market growth is likely to grow radically in the next 5 years.
Although the pharmaceutical industry remains one of the most profitable and stable industries in the world, several variables are forcing fundamental changes in its structure. They are: 
  • Increasing government-imposed price reductions in prices
  • An increasing role of generic substitutes (especially in Europe)
  • The emergence of bio-pharmaceuticals and the bio-omics revolution
  • Increasing buyer power of third-party payers, government buyers, and health maintenance organizations
  • Increased health awareness among patients and government buyers
  • Changing suppliers—enhanced outsourcing, in-licensing, contract research, and manufacturing activities.
Additionally, changing world demographics are influencing the pharmaceutical industry. They include population aging, declining research and development (R&D) productivity, and the General Agreements on Tariffs and Trade (GATT) and Trade Related Intellectual Property Rights (TRIPS).
This report is directed at decision-makers in each industry segment, as well as at individuals and organizations considering investing in drug discovery or drug discovery technology. These people include, but are not limited to the following: 
  • Business development professionals
  • Venture capitalists
  • Merger and acquisition executives
  • Market and product management professionals
  • Chief scientists and technical officers
  • Equipment manufacturers
  • Reagent suppliers
The scope of this study encompasses the major sectors of the world pharmaceutical industry and major geographical markets. BCC Research has analyzed the forces affecting the world pharmaceutical markets, determined their impact on the market demand and growth, and also presented the growth forecast over the next 5 years. Key forces include the increasing role of substitutes (generic pharmaceuticals), threat of new entrants (biopharmaceuticals), increasing role of buyers (governments, insurance, etc.), and changing suppliers.
BCC Research has provided the comprehensive analyses of the industry on the worldwide basis and also provided the detailed profiles for 25 leading pharmaceutical markets across the globe. For each of the geographical markets, we have presented the sector information, pharmaceutical distribution and pricing, and reimbursement and regulations. In a nutshell, the report provides the reader with a one-stop analysis of the worldwide pharmaceutical industry.
Market data and other information used in this report was gathered from interviews with individuals in the industry, as well as a thorough review of technology and markets gathered from secondary sources. These sources include company annual, 10K and 10Q reports, company literature, trade literature, trade associations, and online sources. Note that the author of this report is herself involved in the development of a compound for amyotrophic lateral sclerosis.
Projections were based on current and historical levels of funding and revenues, potential end users, likely unit prices and rates of consumption. Final projections are based on the analysis of information from primary and secondary sources. All currency conversions were made based on the average value of the dollar during the last month of the year in question. In some cases, data is provided in the original currency for readers wishing to make their own comparisons. An online currency converter was used for this purpose. All forecasts are presented in year 2008 constant dollars.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Note: Reports are discounted or included with certain Memberships. See Membership Options.
Published - Apr-2004| Analyst - Mehta Meghna| Code - PHM037A

Report Highlights

  • The world pharmaceutical industry stood at $592 billion in 2003, or 24% of the healthcare sector. Rising at an average annual growth rate (AAGR) of 8.8%, this market is expected to reach $938 billion in 2008.
  • Ethical pharmaceuticals account for 74% of the market. This sector is under increasing pressure from generics and biopharmaceuticals.
  • The generic industry is expected to increase its penetration in the world market to 7% by 2008, reaching $64 billion.
  • Ten geographical markets account for 70% of the ethical sector.
  • Biopharmaceuticals are growing at double the rate of the ethical sector.


Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report